Vraylar vs Caplyta
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Vraylar | US Caplyta | |
|---|---|---|
| Generic name | cariprazine | lumateperone |
| Drug class | Atypical Antipsychotic | Atypical Antipsychotic |
| Treats | Bipolar disorder, schizophrenia, depression (add-on) | Schizophrenia, bipolar depression |
| Category | Mental Health | Mental Health |
| Manufacturer | AbbVie | Intra-Cellular Therapies |
| Year approved | 2015 | 2019 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $200M | $130M |
| Common side effects | Movement disorders, Drowsiness, Restlessness, Weight changes | Drowsiness, Dry mouth, Dizziness, Nausea |
Frequently asked questions
Is Vraylar or Caplyta better?
Neither is universally "better." Vraylar (cariprazine) and Caplyta (lumateperone) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vraylar and Caplyta?
Vraylar is a Atypical Antipsychotic made by AbbVie, while Caplyta is a Atypical Antipsychotic made by Intra-Cellular Therapies. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vraylar has the larger estimated TV advertising budget of the two.